Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry — María Asunción Esteve‐Pastor (2022) | RDL Network
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry
Article 2022 en
Authors
ME
María Asunción Esteve‐Pastor
JR
José Miguel Rivera‐Caravaca
VR
Vanessa Roldán
Abstract
1 min read
In a prospective real-world AF population under rivaroxaban from EMIR registry, the HAS-BLED score had good predictive performance and calibration compared with ORBIT score for MB events. ORBIT score presented worse calibration than HAS-BLED in this DOAC treated population.
María Asunción Esteve‐Pastor, Amaya García-Fernández, Manuel Macı́as, Francisco Sogorb, Mariano Valdés, Vanessa Roldán, Javier Muñiz, Lina Badimón, Inmaculada Roldán, Vicente Bertoméu, Ángel Cequier, Professor Gregory Lip, Manuel Anguita, Francisco Marı́n
Discussion(0)
No comments yet. Be the first to comment.